Feasibility and Safety of Sodium Glucose Cotransporter-2 Inhibitors in Adults with Heart Failure after the Fontan Procedure
Table 2
Changes in clinical data before and after administration of a SGLT-2 inhibitor.
Case
SGLT-2 inhibitor
Duration of SGLT-2inhibitor administration (months)
Data acquisition timing
Weight (kg)
HR (min-1)
SO2 (%)
Mean BP (mmHg)
HbA1C (%)
Ht (%)
Platelet (×109/L)
Albumin (g/dL)
Total bilirubin (mg/dL)
AST (IU/dL)
γGTP (IU/dL)
Na (mmol/L)
Creatinine (mg/dL)
eGFR (mL/min/1.73m2)
BNP (pg/mL)
1
Dapagliflozin 5 mg
3
Before
55
85
83
86
5.6
43
0.93
3.3
4.6
50
155
140
1.02
64
193
After
53
87
91
87
—
44
0.78
3.1
3.9
45
139
141
1.28
50
277
2
Empagliflozin 10 mg
20
Before
80
114
91
93
7.3
52
3.15
2.9
1.5
26
32
138
1.21
56
231
After
85
83
92
90
7.7
56
3.30
3.4
0.5
48
51
139
1.12
60
7
3
Dapagliflozin 5 mg
12
Before
116
91
85
86
6.5
41
1.57
2.8
1.0
41
78
140
0.84
72
52
After
106
83
89
85
6.3
53
1.18
3.8
2.7
45
138
140
0.97
140
57
4
Dapagliflozin 5 mg
2
Before
34
92
81
93
3.2
35
2.35
1.8
0.1
16
17
137
0.60
113
43
After
33
94
79
94
—
32
2.97
2.0
0.1
17
17
132
0.74
137
38
5
Dapagliflozin 5 mg
14
Before
69
103
88
84
7.8
60
1.64
2.9
1.7
55
108
125
1.52
72
101
After
66
75
92
81
6.6
62
1.57
4.4
2.6
39
62
141
1.07
125
12
value
0.345
0.224
0.138
0.224
—
0.224
0.892
0.079
0.715
0.892
0.224
0.465
0.685
0.500
0.345
value < 0.05 means statistical significance when clinical data were compared before and after administration of a sodium glucose cotransporter-2 inhibitor using the Wilcoxon signed rank test. AST: aspartate aminotransferase; BNP: brain natriuretic peptide; BP: blood pressure; γGTP: gamma-glutamyl transpeptidase; HbA1C: haemoglobin A1C; HR: heart rate; Ht: haematocrit; eGFR: estimated glomerular filtration ratio; SGLT-2 inhibitor: sodium glucose cotransporter-2 inhibitor; SO2: systemic oxygen saturation.
